Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma

Expert Review of Anticancer Therapy

Volumn 12, Issue 9, 2012, Pages 1137-1147

  Brose, Marcia S ^a   Smit, Johannes ^a   Capdevila, Jaume ^a   Elisei, Rossella ^a   Nutting, Christopher ^a   Pitoia, Fabian ^a   Robinson, Bruce ^a   Schlumberger, Martin ^a   Shong, Young Kee ^a   Takami, Hiroshi ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

differentiated thyroid cancer; kinase inhibitor; multidisciplinary team; radioactive iodine refractory; regional treatment guidelines

Indexed keywords

AXITINIB; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IODINE 131; LENVATINIB; LEVOTHYROXINE; MOTESANIB; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; RADIOACTIVE IODINE; SORAFENIB; SUNITINIB; VANDETANIB;

ADVANCED CANCER; CANCER PATIENT; DIARRHEA; DIFFERENTIATED THYROID CANCER; FATIGUE; GEOGRAPHIC DISTRIBUTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; SKIN TOXICITY; SPECIALIZATION; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CARCINOMA; DISEASE MANAGEMENT; DISEASE PROGRESSION; DISEASE RESISTANCE; HUMANS; INTERNATIONAL COOPERATION; IODINE RADIOISOTOPES; NEOPLASM GRADING; NEOPLASM STAGING; PATIENT CARE TEAM; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REGIONAL MEDICAL PROGRAMS; THYROID NEOPLASMS;

EID: 84867965962     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.96     Document Type: Review

References (37)

1. Kilfoy BA, Zheng T, Holford TR et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20(5), 525-531 (2009).
2. Sherman SI. Thyroid carcinoma. Lancet 361(9356), 501-511 (2003). (Pubitemid 36173719)
3. Cooper DS, Doherty GM, Haugen BR et al.; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167-1214 (2009).
4. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91(8), 2892-2899 (2006). (Pubitemid 44271732)
5. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxyd- glucose-positron emission tomography scanning. J. Clin. Endocrinol. Metab. 91(2), 498-505 (2006). (Pubitemid 43236915)
6. Tuttle RM, Leboeuf R, Shaha AR. Medical management of thyroid cancer: a risk adapted approach. J. Surg. Oncol. 97(8), 712-716 (2008). (Pubitemid 351812974)
7. Elisei R, Molinaro E, Agate L et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J. Clin. Endocrinol. Metab. 95(4), 1516-1527 (2010).
8. Eustatia-Rutten CF, Corssmit EP, Biermasz NR et al. Survival and death causes in differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 91(1), 313-319 (2006). (Pubitemid 43069155)
9. Elisei R, Ugolini C, Viola D et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J. Clin. Endocrinol. Metab. 93(10), 3943-3949 (2008).
10. Kebebew E, Weng J, Bauer J et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg. 246(3), 466-470; discussion 470 (2007).
11. Hodak SP, Carty SE. Radioiodine-resistant differentiated thyroid cancer: hope for the future. Oncology 23(9), 775-776 (2009).
12. Pfister DG, Fagin JA. Refractory thyroid cancer: a paradigm shift in treatment is not far off. J. Clin. Oncol. 26(29), 4701-4704 (2008).
13. Matuszczyk A, Petersenn S, Bockisch A et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm. Metab. Res. 40(3), 210-213 (2008). (Pubitemid 351690526)
14. Argiris A, Agarwala SS, Karamouzis MV et al. A Phase II trial of doxorubicin and interferon alpha 2b in advanced, nonmedullary thyroid cancer. Invest. New Drugs 26(2), 183-188 (2008). (Pubitemid 351357713)
15. Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56(9), 2155-2160 (1985). (Pubitemid 16236586)
16. Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154(6), 787-803 (2006). (Pubitemid 43997716)
17. Pitoia F, Ward L, Wohllk N et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq. Bras. Endocrinol. Metabol. 53(7), 884-887 (2009).
18. Takami H, Ito Y, Okamoto T, Yoshida A. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J. Surg. 35(1), 111-121 (2011).
19. Luster M, Clarke SE, Dietlein M et al. European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 35(10), 1941-1959 (2008).
20. Onconline. Cancer Clinical Practice Guidelines. v1.0. (2007).
21. Borson-Chazot F, Bardet S, Bournaud C et al.; Expert Group for French Recommendations for the Management of Differentiated Thyroid Carcinomas of Vesicular Origin. Guidelines for the management of differentiated thyroid carcinomas of vesicular origin. Ann. Endocrinol. 69(6), 472-486 (2008).
22. Yi KH, Park YJ, Koong SS et al. Revised Korean Thyroid Association management guidelines for patients with thyroid nodules and thyroid cancer. J. Korean Thyroid Assoc. 3, 065-096 (2010).
23. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009).
24. Fassnacht M, Kreissl MC, Weismann D, Allolio B. New targets and therapeutic approaches for endocrine malignancies. Pharmacol. Ther. 123(1), 117-141 (2009).
25. Vasko VV, Saji M. Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis. Curr. Opin. Oncol. 19(1), 11-17 (2007). (Pubitemid 44885594)
26. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev. Mol. Diagn. 8(1), 83-95 (2008).
27. Keefe S, Troxel A, Rhee S et al. Phase II trial of sorafenib in patients with advanced thyroid cancer. J. Clin. Oncol. 29(Suppl.), Abstract 5562 (2011).
28. Kloos RT, Ringel MD, Knopp MV et al. Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 27(10), 1675-1684 (2009).
29. Hoftijzer H, Heemstra KA, Morreau H et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 161(6), 923-931 (2009).
30. Ahmed M, Barbachano Y, Riddell A et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a Phase II study in a UK based population. Eur. J. Endocrinol. 165(2), 315-322 (2011).
31. Capdevila J, Iglesias L, Halperin I et al. Sorafenib in metastatic thyroid cancer. Endocr. Relat. Cancer 19(2), 209-216 (2012).
32. Carr L, Goulart B, Martins R et al. Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary throid carcinoma (MTC) and welldifferentiated thyroid cancer (WDTC). J. Clin. Oncol. 27, Abstract 6056 (2009).
33. Ravaud A, de la Fouchardiere C, Courbon F et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU Phase II trial. J. Clin. Oncol. 26, Abstract 6058 (2008).
34. Cohen EE, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a Phase II study. J. Clin. Oncol. 26(29), 4708-4713 (2008).
35. Sherman SI, Wirth LJ, Droz JP et al. Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N. Engl. J. Med. 359(1), 31-42 (2008). (Pubitemid 351931094)
36. Bible KC, Suman VJ, Molina JR et al. Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase II Consortium. Efficacy of pazopanib in progressive, radioiodinerefractory, metastatic differentiated thyroid cancers: results of a Phase II consortium study. Lancet Oncol. 11(10), 962-972 (2010).
37. Sherman SI, Jarzab B, Cabanillas ME et al. A Phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J. Clin. Oncol. 29, Abstract 5503 (2011).